The p53 tumor suppressor protein can adopt both latent, non-DNA binding and active, DNA binding forms, and p53 activity is thought to be regulated in cells, at least in part, through a conformational shift which leads to sequence speci®c DNA binding. In vitro, this allosteric regulation of DNA binding by p53 has been shown to be mediated through the C-terminus of the protein. We show here that although deletion of the C-terminal 16 amino acids of p53 did not activate DNA binding, deletion of a further eight amino acids resulted in constitutive activation of DNA binding activity. Simultaneous mutation of the three lysine residues within these eight amino acids also resulted in constitutive DNA binding activity, although this was reduced when only two of these lysines were altered. The deletion or point mutants of p53 showing constitutive DNA binding activity did not display clear evidence of DNA binding site speci®city, although some binding site preference was seen with the point mutants. Each of the constitutively active p53 mutants retained transcriptional activity and induced both cell cycle arrest and apoptosis in transiently transfected cells at rates comparable with the wild type protein.
Introduction
The p53 protein functions under conditions of stress such as DNA damage or hypoxia and plays a role in preventing cellular replication or activating apoptotic death in damaged cells . Loss of p53 function is a common event in many types of human cancer (Hollstein et al., 1994) and p53 is thought to guard against the outgrowth of potentially malignant cells (Lane, 1992) . Although there is evidence that p53 functions through several mechanisms, it is clear that the ability of p53 to act as a sequence speci®c transcriptional activator can play an important role in mediating both cell cycle arrest and apoptosis Sabbatini et al., 1995; Attardi et al., 1996; Rowan et al., 1996) . Activation of p53 results in protein accumulation due, in part, to an increase in the half life of p53, and a concomitant elevation of p53 dependent transcriptional activity. Control of protein level is not the only mechanism by which this function of p53 can be regulated, however, and the latent form of p53 expressed in uninduced cells can be activated for DNA binding in the absence of overall increases in protein level Lu et al., 1997; Sun et al., 1997) . Previous studies have shown that a negative regulatory domain in the C-terminus of the p53 protein is responsible for the maintenance of the latent, non-DNA binding form of the protein and an allosteric regulation model has been proposed in which, in the context of a tetramer of p53, the C-terminal regulatory domain can interact with another region of p53, and maintain the protein in a non-DNA binding conformation (Hupp et al., 1992; Hupp and Lane, 1994) . Disruption of this interaction allows activation of DNA binding and there is evidence that this may be achieved through truncation of the Cterminal domain, phosphorylation, glycosylation or acetylation within this region, binding of antibodies, interaction with single stranded DNA or peptides derived from the C-terminal sequence (Hupp et al., 1992 Jayaraman and Prives, 1995; Shaw et al., 1996; Gu and Roeder, 1997) . Redox dependent regulation of p53 DNA binding has also been described (Hainault and Milner, 1993) as has an alternative to the allosteric model, based on a role for nonspeci®c DNA binding by the Cterminus of p53 (Anderson et al, 1997) . The physiological mechanism by which p53 is activated from the latent to the DNA binding form is not clear, although phosphorylation, recognition of damaged DNA, regulation by redox/repair proteins such as Ref-1 (Jayaraman et al., 1997) or acetylation following interaction with the coactivator p300 (Gu and Roeder, 1997) are promising candidates. Many mutant forms of p53 expressed in tumors have lost DNA binding activity, although it is possible to re-activate this function in some cases following antibody binding to the C-terminus of the mutant proteins (AbarzuÂ a et al., 1995; or using a peptide derived from the C-terminal regulatory domain (AbarzuÂ a et al., 1996; Selivanova et al., 1997) . The possibility of re-activating p53 function in some tumor cells has great therapeutic potential, since expression of p53 function is likely to result in cell cycle arrest or apoptotic death of the cell.
Although transcriptional activation by p53 plays a role in mediating both cell cycle arrest and apoptosis, it seems clear that these are separable functions of p53. Some p53 mutants which retain cell cycle arrest but not apoptotic function have been shown to retain the ability to activate expression of p53 response genes which are thought to contribute to cell cycle arrest, such as the cyclin dependent kinase inhibitor p21 Waf1/Cip1 , whilst losing the ability to activate other p53 target genes, such as Bax and IGF-BP3, which might play a role in mediating the apoptotic response (Friedlander et al., 1996; Ludwig et al., 1996) . This dierence in transcriptional activity is due to dierential binding to the p53 target sites in the promoters of these genes, suggesting that the wild type p53 protein may also show promoter selectivity under certain circumstances. In support of this model, phosphorylation of p53 at the cyclin dependent kinase phosphorylation site allowed selective binding of p53 to certain DNA target sequences (Wang and Prives, 1995) .
In this study we have identi®ed several C-terminal mutants of p53 that constitutively activate DNA binding, with a particular importance of the region 370 ± 378 and the three lysine residues within this region which have been shown to be acetylated by p300 (Gu and Roeder, 1997) . p53 mutants which displayed constitutive DNA binding functioned like wild type in transcriptional activation, cell cycle arrest and apoptosis assays. 
Results

DNA binding
Previous studies have shown p53 is translated in vitro in a latent, non-DNA binding form which can be activated through interaction with the monoclonal antibody PAb421 Crook et al., 1996) . Deletion of the C-terminal 30 amino acids of p53 was shown to activate the in vitro DNA binding activity, although deletion of the C-terminal four amino acids was not sucient for this activity . These studies suggested that the negative regulatory domain resides in the basic region between residues 370 and 386, sequences containing the epitope recognized by the monoclonal antibody PAb421 and the binding site for DnaK (Hupp et al., 1992) . To further analyse the contribution of C-terminal p53 sequences to the regulation of DNA binding function, we analysed a series of p53 mutants described in Figure 1a . The mutants were expressed following in vitro translation at comparable levels and although they were all detected eciently by antibody PAb1801, which recognizes an N-terminal epitope within the p53 protein (Banks et al., 1986) , most of them showed loss of the C-terminal epitope recognized by the PAb421 (Wade-Evans and Jenkins, 1985) (Figure 1b) . We analysed the mutants for their ability to interact with a consensus p53 binding site oligonucleotide ( Figure  1c ). As shown previously, wild type p53 was unable to bind DNA unless activated through interaction with PAb421, and truncation of the C-terminal 24 amino acids to the end of the conserved basic domain (D370) constitutively activated p53 DNA binding, resulting in a p53/DNA complex which can be supershifted with the N-terminal antibody PAb1801 ( Figure 1c ). Since peptide analysis pointed to the importance of positively charged residues , we examined the DNA binding activity of p53 proteins carrying point mutations within these residues. Mutation of the ®rst three lysine residues within this domain to isoleucine (I370/372/373) resulted in the activation of DNA binding function, as did alterations of amino acids 365, 372, 379 and 387 (ALAL).
However, activation of DNA binding does not simply re¯ect a loss of positive charge since p53 with mutation of lysine 381, 382 and 386 (I381/382/386) (previously reported by Crook et al., 1996) , or substitution of residues 373, 380 and 388 (LLL) remained in the latent form ( Figure 1c ). To further de®ne the role of lysine in the region 370 to 373, we constructed a variant of mutant ALAL in which the only ®rst two mutations were retained (AL). Unlike the quadruple mutant, this double mutant was maintained in the latent, non DNA binding state, indicating that a single substitution of lysine 372 is not sucient for constitutive DNA binding activity in the full length protein (Figure 1c) .
Analysis of the p53 mutants pointed to an importance of lysine residues 370, 372 and 373 in maintaining p53 in a latent form. Two mutants with substitutions of lysine 372 (AL) or 373 (LLL), however, failed to show constitutive DNA binding activity and it was possible that these particular alterations might result in loss of all DNA binding activity. Since these mutants could not be activated for DNA binding through interaction with PAb421 (Figure 1b) , we con®rmed that they were not entirely defective for DNA binding by activation with a peptide derived from C-terminal p53 sequences from amino acid 369 ± 382 (Figure 1d ). This demonstrated that, like wild type p53, both AL and LLL mutants were translated in a latent form which could be activated for DNA binding.
Although studies with peptides showed that most of the basic residues within the C-terminal region of p53 could contribute to the maintenance of the latent state, our data suggested a relatively greater contribution of the ®rst three lysine residues (370, 372 and 373) compared to the last three lysine residues (381, 382, 386) in more detail we constructed further mutants ( Figure  2a ). Analysis of a deletion mutant which lacked the Cterminal 16 amino acids (D378) showed that, unlike the p53 mutant lacking the C-terminal 24 amino acids (D370), this mutant was not constitutively activated for DNA binding (Figure 2b ). The observation that both AL and LLL mutants remained in the latent form (Figure 1 ) suggested that alteration of only lysine residues 372 or 373 alone was not sucient to activate DNA binding. We therefore tested mutants in which the lysine residues were substituted in pairs (Figure 2a ) and found that altering only two of the three lysines reduced the constitutive DNA binding activity seen with the triple mutant, although weak constitutive binding activity was detected in both I370/372 and I370/373 mutants (Figure 2c) . DNA binding by each of these mutant was seen following incubation with the peptide, and it is of interest to note that DNA binding of all the constitutively active mutants, including D370, was further enhanced by the addition of the peptide (Figure  2b and c). Given the apparent importance of charge to the regulation of DNA binding, we also considered the possibility that mutant I370/372/373 resulted in the loss of kinase recognition for the phosphorylation of serine 371, a putative target for phosphorylation by PKC. However, mutation of this serine to either alanine or aspartic acid failed to constitutively activate DNA binding, although these mutants retained the PAb421 epitope and could be activated for DNA binding like the wild type protein (Figure 2d ). These results indicate that Figure 5 Western blot analysis of Saos-2 cells transiently expressing wild type p53 and the indicated mutant proteins. Levels of expression of the transfected p53, and the endogenous p21 Waf1/Cip1 proteins are shown. Each p53 transfection was carried out in duplicate phosphorylation of this site is unlikely to be necessary in maintaining p53 in the latent form.
Several studies have shown that some p53 mutants can show binding site preference and phosphorylation at the cdk site or mutation within the DNA binding domain can selectively alter the ability of p53 to bind to sequences present in cell derived p53 responsive promoters (Wang and Prives, 1995) . In particular, it is possible to dierentiate between promoters driving cell cycle arrest genes, such as p21 Waf1/Cip1 , and promoters regulating genes which may mediate p53 apoptosis, such as Bax and IGF-BP3 (Friedlander et al., 1996; . We therefore tested oligonucleotides representing p53 binding sites from several promoters to determine whether the mutants described here were constitutively activated for binding to all p53 sites or whether they too showed selectivity (Figure 3) . Analysis of p53 binding sequences from the p21 Waf1/Cip1 (Figure  3a) , Bax (Figure 3b ) and IGF-BP3 (Figure 3c ) promoters showed that each of the constitutively activated p53 mutants (D370, ALAL and I370/372/ 373) retained the ability to bind to all of these sequences, suggesting that this regulatory domain does not aect DNA site speci®city. Interestingly, as with the consensus binding site (Figure 1c ), the two point mutants ALAL and I370/372/373 showed a reduced ability to interact with the binding site derived from the p21 Waf1/Cip1 and IGF-BP3 promoters compared to the truncation mutant D370. This reduced binding was not apparent with the Bax derived p53 binding site.
Transcriptional trans-activation
Analysis in transient transfection assays showed that each of the p53 mutant retained the ability to activate transcription from several p53 responsive promoters controlling the expression of a reporter genes (Figure 4) . A C-terminal deletion mutant impinging on the oligomerization domain (D347) was defective for transcriptional activity and used as a negative control. Although there were no striking dierences in the ability of these mutants to activate transcription from any of the promoter sequences tested, the truncation mutant D370, which showed some evidence for relatively stronger DNA binding (Figure 3) , consistently showed slightly enhanced ability to activate other promoters such as Mdm2 or the synthetic PG13 (Figure 4) . We did note that one of the C-terminal point mutants (ALAL) consistently showed a relatively lower transcriptional activation of the Bax promoter when transfecting low amounts of plasmid (50 ng, Figure 4d ), although increasing plasmid concentrations con®rmed that this mutant retained the ability to activate this promoter (Figure 4e ). We con®rmed that each of the mutants activated for DNA binding also retained the ability to activate expression of an endogenous p53 target, p21
Waf1/Cip1 compared to a transcriptionally inactive p53 truncation mutant D347 (Figure 5 ). Once again, some evidence for slightly enhanced activity of the D370 mutant was seen.
Cell cycle arrest and apoptosis
Many previous studies have shown a close correlation between p53 transciptional activation and induction of a G1 block to cell cycle progression, and it is likely that activation of genes such as p21
Waf1/Cip1 is a principle mechanism by which p53 induces a cell cycle arrest (Brugarolas et al., 1995; Deng et al., 1995; Waldman et al., 1995) . The role of transciptional activation to the apoptotic response is less straightforward and although it seems likely that transcriptional activation of apoptotic targets by p53 plays an important role in this response in many cell types, there is also evidence that transcriptionally independent p53 functions contribute to the activation of cell death (Caelles et al., 1994; Haupt et al., 1995) . It is apparent, however, that induction of cell cycle arrest and induction of apoptosis represent separate p53 induced pathways, and the implementation of a G1 arrest is neither necessary or sucient for the apoptotic response (Haupt et al., 1995; Rowan et al., 1996) . Rather than contributing to cell death, it is possible that activation of p21
Waf1/Cip1 and a strong G1 arrest response may protect p53 expressing cells from activation of the apoptotic pathway (Gorospe et al., 1997) . Since cell cycle arrest is very clearly a consequence of p53 transcriptional activation by p53, we analysed the relative apoptotic and cell cycle arrest activities of the constitutive DNA binding mutants to determine whether there is any defect or shift in the activation of either response. Expression of p53 in Saos-2cells, followed by FACS analysis of the p53 expressing cells showed that each of the p53 mutants retained both cell cycle arrest and apoptotic activity comparable to the wild type protein (Figure 6a and b) . By comparison, a C-terminal deletion mutant lacking the oligomerization domain (D291) did not activate apoptosis and did not increase the percentage of cells in the G1 phase of the cell cycle above that seen in untransfected cells. Futhermore, there was no evidence that p53 proteins with constitutive DNA binding activity favor one response over the other compared to the wild type protein.
Discussion
We have identi®ed several residues at the C-terminus of p53 which contribute to the maintenance of the latent, Deletion analysis showed that although removal of the C-terminal 16 amino acids of p53 was not sucient to clearly activate DNA binding, truncation of a further eight amino acids resulted in constitutive DNA binding activity. Closer examination of these eight amino acids showed that substitution of the three lysine residues also activated DNA binding of p53, although this was reduced when only two lysines were mutated. Previous analyses of the ability of peptides derived from this region of p53 to activate DNA binding illustrated an important role for lysines 370, 372, 373, 381 and 382. Interestingly, these lysine residues were subsequently shown to be acetylated by p300, a coactivator which binds to the N-terminus of p53, resulting in activation of DNA binding (Gu and Roeder, 1997) . Analysis of mutant peptides demonstrated that alteration of any one of these lysine residues severely impaired the ability of the peptide to activate p53 , although our results suggest that in the context of the full length protein, lysines 370, 372 and 373 play a more signi®cant role in maintaining the latent form than lysines 381 and 382. It is likely that this re¯ects quantitative, rather than qualitative dierences in the contribution of these residues, and that alteration of lysines 381 and 382 results in a weaker activation of DNA binding, below the level of detection in our assays. Consistent with this, analysis of bacterially expressed p53 proteins in assays where the concentration of p53 is signi®cantly higher than that achieved following in vitro translation of the protein as used here, showed that the I381/382/ 386 mutant described here displayed weak constitutive DNA binding activity (Klas Wiman, personal communication).
Some point mutations within the sequence speci®c DNA binding core of p53 result in dierential loss of the ability to bind to certain DNA binding sites and a concomitant loss of the ability to activate expression from certain cellular promoters (Friedlander et al., 1996; Ludwig et al., 1996) . This has been linked to loss of apoptotic, but not cell cycle arrest function and has lead to the suggestion that modi®cations of wild type p53 may also result in a similar dierential function. We show here that constitutive activation of DNA binding through mutation within the C-terminus of p53 does not result in obvious speci®city in terms of DNA sequence, suggesting that promoter choice is not regulated through these sequences. However, truncation of the C-terminal 24 amino acids of the p53 protein appeared to activate DNA binding somewhat more eciently than point mutation within this region and this mutant also showed slightly enhanced transcriptional activity.
It is clear that the cell cycle arrest and apoptotic activities of p53 are separable functions, with some evidence that activation of p21
Waf1/Cip1 and cell cycle arrest may protect from apoptosis (Gorospe et al., 1997) . Although all of the constitutively activated p53 mutants retained the ability to interact with the p21 it has been demonstrated that transfection of cells results in the activation of endogenous p53 (Renzing and Lane, 1995) and it is also possible that all the exogenous p53 proteins expressed in these assays are activated for DNA binding function, by virtue of the method of introduction into the cells. Although latent and DNA binding forms of p53 can be clearly identi®ed in vitro, the regulation of DNA binding in cells is less well understood. The observations that low levels of p53 can become active for DNA binding, either following DNA damage Lu et al., 1997; Sun et al., 1997) or during dierentiation (Weinberg et al., 1995) , and that high levels of wild type p53 can remain inactive in some tumors (Lutzker and Levine, 1996) supports a role for allosteric regulation of p53 function in vivo. However, the mechanisms underlying this regulation remain unclear, although recent models suggesting that p53 regulates its own stability through activation of Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997) imply that p53 can be transcriptionally active in normal as well as damaged cells. It seems likely that transient assays involving over-expression of p53 from strong heterologous promoters are insuciently sensitive to clearly detect dierences in activity between wild type p53 and mutants showing constitutive DNA binding. Nevertheless, identi®cation of residues within p53 which play a role in regulating the DNA binding activity of the protein should prove useful in determining the contribution of this level of regulation to this normal p53 response.
Materials and methods
Plasmids
p53 sequences were expressed from either the SP6 promoter in pGEM, for in vitro expression, or from the cytomegalovirus early promoter for expression in cells. Wild type p53 and the deletion mutants D370, D347 and D291 (Marston et al., 1995) , point mutants I370/372/373 and I381/382/386 (Crook et al., 1996) and point mutants ALAL and LLL (Tarunina and Jenkins, 1993) have been described previously. Oligonucleotide-directed mutagenesis was used as previously described to generate p53 point mutants in which serine 371 is substituted for either alanine (371A) or aspartic acid (371D). PCR based mutagenesis was used to generate I370/372, I370/373, I372/373 and D378. Transcriptional activity of the p53 proteins was assessed using reporter constructs in which the luciferase gene is regulated by a p53-inducible promoter. These reporters contained p53 responsive sequences from cellular promoters controlling expressing of human p21
Waf1/Cip1 in pWWP-luc (El-Deiry et al., 1993) , human Bax in Bax-Luc, derived from Bax-CAT (Miyashita and Reed, 1995) , and mouse Mdm2 in pGL2NA(mdm2)-luc (Juven et al., 1993) . A reporter containing repeats of a consensus p53 binding site, PG13-luc (El-Deiry et al., 1993) was also used.
DNA binding
The DNA binding activities of in vitro translated p53 proteins were analysed by electrophoretic mobility shift assays as previously described (Crook et al., 1996) . Oligonucleotides encoding two p53 consensus binding sites (PG13) or p53 binding sequences from the p21 Waf1/Cip1 promoter, the Bax promoter or the IGF-BP3 promoter have been described previously . p53 proteins were activated for DNA binding by incubation with the C-terminal monoclonal antibody PAb421 (Hupp et al., 1992) and p53/DNA complexes were supershifted the N-terminal antibody PAb1801 (Crook et al., 1996) . Where appropriate, DNA binding was activated following incubation with a peptide derived from p53 sequences from amino acid 369 ± 382, as previously described .
Cell culture and transfection p53-null human Saos-2 cells were maintained in DMEM supplemented with 10% fetal calf serum. For transient transfections, cells were seeded at 3610 5 ± 8610 5 per 10 cm petri dish and transfected the following day using calcium phosphate coprecipitation. For luciferase assays 50 ng or 500 ng of each p53 plasmid was co-transfected with 5 mg of each reporter construct. For¯ow cytometry 10 mg of each p53 plasmid was transfected.
Transcriptional activity and protein analysis
Cells were harvested 24 h post transfection and analysed for luciferase activity as previously described (Lam and Waston, 1993) . For Western blotting, equal amounts of lysate were subject to polyacrylamide gel electrophoresis, and following transfer to nitrocellulose ®lters, the proteins were detected with the p53 speci®c monoclonal antibody DO-1 (Vojtesek et al., 1992) and the p21 Waf1/Cip1 speci®c monoclonal antibody SX118 (Fredersdorf et al., 1996) . In vitro translated, 35 S-methionine labeled p53 proteins were immunoprecipitated with either PAb1801 or PAb421 (Oncogene Science) as previously described (Marston et al., 1995) .
Flow cytometry
Cell cycle characteristics of p53 transfected cells were assessed by¯ow cytometry as previously described (Rowan et al., 1996) . Brie¯y, cells were harvested 24 h posttransfection, ®xed and stained for p53 using PAb1801 and for DNA content using propidium iodide. Samples were analysed in a¯ow cytometer (FACScalibur: Beckton Dickinson) and cells were measured for their FITC uorescence intensity (green channel) and propidium iodide¯uorescence (red channel). Total populations were gated to remove doublets and very small debris, and p53 expressing, high FITC¯uorescing cells were gated and cell cycle analysis carried out using CellQuest analysis software. Apoptosis induced by each p53 protein was expressed as the percentage of cells with a sub-G1 DNA content in excess of that seen in the untransfected population (usually around 2%). Precentage of cells in G1 was calculated for the remaining non-apoptotic population and compared to that seen in the untransfected population.
